{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:14:10Z","timestamp":1718583250740},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Particle Therapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijpt.2024.100015","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T01:49:28Z","timestamp":1713923368000},"page":"100015","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"Robert W.","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiasen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Pisansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon J.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Stish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman O.","family":"Kowalchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan P.","family":"McMenomy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Waddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijpt.2024.100015_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ijpt.2024.100015_bib2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.juro.2014.06.017","article-title":"Current clinical presentation and treatment of localized prostate cancer in the United States","volume":"192","author":"Mahmood","year":"2014","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.ijpt.2024.100015_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2013.185","article-title":"Evolution of advanced technologies in prostate cancer radiotherapy","volume":"10","author":"Zaorsky","year":"2013","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.ijpt.2024.100015_bib4","doi-asserted-by":"crossref","first-page":"P1013","DOI":"10.1016\/j.ijrobp.2004.04.014","article-title":"Fractionation and late rectal toxicity","volume":"60","author":"Brenner","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.ijpt.2024.100015_bib5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited an analysis of clinical results from 14 168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol ((Madr))"},{"issue":"4","key":"10.1016\/j.ijpt.2024.100015_bib6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.ijpt.2024.100015_bib7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ijpt.2024.100015_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ijpt.2024.100015_bib9","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ijpt.2024.100015_bib10","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ijpt.2024.100015_bib11","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ijpt.2024.100015_bib12","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of hypofractionated, dose-escalated, Intensity-Modulated Radiation Therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10196","key":"10.1016\/j.ijpt.2024.100015_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijpt.2024.100015_bib14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ijpt.2024.100015_bib16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijpt.2024.100015_bib18","doi-asserted-by":"crossref","unstructured":"van As N, Tree A, Patel J, et al. Five-year outcomes from PACE B: an International Phase III Randomized Controlled Trial comparing Stereotactic Body Radiotherapy (SBRT) vs. conventionally fractionated or moderately hypofractionated external beam radiotherapy for localized prostate cancer. In: American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting; 2023.","DOI":"10.1016\/j.ijrobp.2023.08.027"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20471","article-title":"Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States","volume":"3","author":"Mahase","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41391-019-0191-9","article-title":"Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: a National Cancer Database Analysis","volume":"23","author":"Malouff","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"21","key":"10.1016\/j.ijpt.2024.100015_bib21","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.34450","article-title":"Cost effectiveness of treatment strategies for high risk prostate cancer","volume":"128","author":"Kowalchuk","year":"2022","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijpt.2024.100015_bib22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ijrobp.2007.07.2335","article-title":"Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer","volume":"70","author":"Vargas","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ijpt.2024.100015_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ijrobp.2009.01.044","article-title":"Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer","volume":"75","author":"Chera","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2007.03.018","article-title":"Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison","volume":"69","author":"Trofimov","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ijpt.2024.100015_bib25","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ijrobp.2004.12.052","article-title":"Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy","volume":"62","author":"Vargas","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.radonc.2014.01.007","article-title":"Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer","volume":"110","author":"Stenmark","year":"2014","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ijpt.2024.100015_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijrobp.2010.09.058","article-title":"Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity","volume":"82","author":"Pederson","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2015.10.003","article-title":"Urinary symptoms following external beam radiotherapy of the prostate: dose-symptom correlates with multiple-event and event-count models","volume":"117","author":"Yahya","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijpt.2024.100015_bib29","first-page":"34","article-title":"Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer","volume":"31","author":"Kowalchuk","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ijpt.2024.100015_bib30","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijrobp.2009.07.011","article-title":"Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy","volume":"77","author":"Yoon","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ijrobp.2009.01.001","article-title":"Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer","volume":"74","author":"Fontenot","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ijpt.2024.100015_bib32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijrobp.2013.11.007","article-title":"Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer","volume":"88","author":"Mendenhall","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijpt.2024.100015_bib33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2016.02.038","article-title":"Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer","volume":"95","author":"Bryant","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ijpt.2024.100015_bib34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cncr.28536","article-title":"Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer","volume":"120","author":"Hoppe","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ijpt.2024.100015_bib35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/0284186X.2017.1287946","article-title":"Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer","volume":"56","author":"Henderson","year":"2017","journal-title":"Acta Oncol ((Madr))"},{"issue":"4","key":"10.1016\/j.ijpt.2024.100015_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijrobp.2019.05.069","article-title":"Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer","volume":"105","author":"Grewal","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0000000000000241","article-title":"Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002","volume":"41","author":"Vargas","year":"2018","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"issue":"1","key":"10.1016\/j.ijpt.2024.100015_bib38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2016.01.018","article-title":"Can we advance proton therapy for prostate? Considering alternative beam angles and relative biological effectiveness variations when comparing against intensity modulated radiation therapy","volume":"95","author":"Underwood","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijpt.2024.100015_bib39","first-page":"80","article-title":"Proton beam therapy delivered using pencil beam scanning vs. passive scattering\/uniform scanning for localized prostate cancer: comparative toxicity analysis of PCG 001-09","volume":"19","author":"Mishra","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijpt.2024.100015_bib40","article-title":"Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy","volume":"5","author":"Guan","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0360-3016(02)02754-2","article-title":"Relative biological effectiveness (RBE) values for proton beam therapy","volume":"53","author":"Paganetti","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijpt.2024.100015_bib42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2011.06.1974","article-title":"Improvement of prostate treatment by anterior proton fields","volume":"83","author":"Tang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ijpt.2024.100015_bib43","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijpt.2024.100015_bib44","unstructured":"National Comprehensive Care Network. Prostate Cancer (Version 1.2023). \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf\u3009. Accessed February 22, 2023."},{"issue":"5","key":"10.1016\/j.ijpt.2024.100015_bib45","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.ijrobp.2016.03.041","article-title":"Clinically applicable Monte Carlo\u2013based biological dose optimization for the treatment of head and neck cancers with spot-scanning proton therapy","volume":"95","author":"Wan Chan Tseung","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijpt.2024.100015_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijpt.2024.100015_bib47","article-title":"Long-term risk of hip complications after radiation therapy for prostate cancer: a dose-response study","volume":"6","author":"Rasmusson","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ijpt.2024.100015_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","article-title":"Impact of age at diagnosis on prostate cancer treatment and survival","volume":"29","author":"Bechis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ijpt.2024.100015_bib49","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ac212c","article-title":"Investigating beam range uncertainty in proton prostate treatment using pelvic-like biological phantoms","volume":"66","author":"Shao","year":"2021","journal-title":"Phys Med Biol"}],"container-title":["International Journal of Particle Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2331518024000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2331518024000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T11:53:47Z","timestamp":1718538827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2331518024000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":49,"alternative-id":["S2331518024000817"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpt.2024.100015","relation":{},"ISSN":["2331-5180"],"issn-type":[{"value":"2331-5180","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Particle Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpt.2024.100015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Particle Therapy Co-operative Group.","name":"copyright","label":"Copyright"}],"article-number":"100015"}}